Eamonn Hobbs ’80 is president and CEO of Delcath Systems Inc. in New York City, which manufactures devices to administer high dose chemotherapy and other therapeutic agents directly to diseased organs or regions of the body. Prior to his appointment, Hobbs was president and CEO of AngioDynamics Inc., a company he co-founded in 1988.
Throughout his 20-year tenure there, Hobbs led its efforts in marketing, strategic planning, product development and general management. Before joining AngioDynamics, Hobbs was the director of marketing and product development at NAMIC; founder, president and CEO of Hobbs Medical Inc., and a product development engineer at Cook Inc.
In 2005, he was granted an honorary fellowship by the Society of Interventional Radiology (SIR) and as an inventor, has had 28 issued U.S. patents and more than 100 issued patents around the world, which have directly led to total revenues of more than $1 billion. Currently Hobbs has over 30 U.S. patents pending.
He continues to support the University through the Eamonn P. Hobbs Endowed Scholarship for Excellence Fund, which supports plastic engineering students.
While he calls Manhattan home, Hobbs travels to Lowell to serve on several committees, including this year’s Commencement Host Committee and the Chancellor’s External Advisory Task Force. He was also a recent speaker at the University’s Plastics Engineering Speakers Series.